Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 6/2012

01-12-2012 | Original Paper

The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications

Authors: José Manuel Rodríguez Barrios, Ferran Pérez Alcántara, Carlos Crespo Palomo, Paloma González García, Enrique Antón De Las Heras, Max Brosa Riestra

Published in: The European Journal of Health Economics | Issue 6/2012

Login to get access

Abstract

Objectives

The objective of this study was to evaluate the methodological characteristics of cost-effectiveness evaluations carried out in Spain, since 1990, which include LYG as an outcome to measure the incremental cost-effectiveness ratio.

Methods

A systematic review of published studies was conducted describing their characteristics and methodological quality. We analyse the cost per LYG results in relation with a commonly accepted Spanish cost-effectiveness threshold and the possible relation with the cost per quality adjusted life year (QALY) gained when they both were calculated for the same economic evaluation.

Results

A total of 62 economic evaluations fulfilled the selection criteria, 24 of them including the cost per QALY gained result as well. The methodological quality of the studies was good (55%) or very good (26%). A total of 124 cost per LYG results were obtained with a mean ratio of 49,529€ and a median of 11,490€ (standard deviation of 183,080). Since 2003, a commonly accepted Spanish threshold has been referenced by 66% of studies. A significant correlation was found between the cost per LYG and cost per QALY gained results (0.89 Spearman-Rho, 0.91 Pearson).

Conclusions

There is an increasing interest for economic health care evaluations in Spain, and the quality of the studies is also improving. Although a commonly accepted threshold exists, further information is needed for decision-making as well as to identify the relationship between the costs per LYG and per QALY gained.
Literature
1.
Oliva, J., del Llano, J., Sacristán, J.A.: Analysis of economic evaluations of health technologies performed in Spain between 1990 and 2000. Gac. Sanit. 16(Suppl 2), 2–11 (2002) (Spanish)PubMed
2.
Sacristán, J.A., Ortun, V., Rovira, J., Prieto, L., García-Alonso, F.: Grupo ECOMED: economic assessment in medicine. Med. Clin. 122, 379–382 (2004) (Spanish)CrossRef
3.
Drummond, M.F., O’Brien, B.J., Stoddart, G.L., Torrance, G.W.: Methods for the Economic Evaluation of Health Care Programs. Oxford University Press, Oxford (2005)
4.
Garcia-Altés, A.: Twenty years of health care economic analysis in Spain: are we doing well? Health Econ. 10, 715–729 (2001)PubMedCrossRef
5.
Rodriguez-Barrios, J.M., Lizán, L., Paz, S.: The use of Quality Adjusted Life Years (QALYs) in the economic evaluation of health technologies in Spain: a review of the 1990–2009 literature. Value Health (accepted for publication)
6.
7.
8.
López-Bastida, J., Oliva, J., Antoñanzas, F., García-Altés, A., Gisbert, R., Mar, J., Puig-Junoy, J.: Spanish recommendations on economic evaluation of health technologies. Eur. J. Health Econ. 11, 513–520 (2010)PubMedCrossRef
9.
Sacristán, J.A., Oliva, J., Del Llano, J., Prieto, L., Pinto, J.L.: What is an efficient health technology in Spain? Gac. Sanit. 16, 334–343 (2002) (Spanish)PubMed
10.
11.
Chapman, R.H., Berger, M., Weinstein, M.C., Weeks, J.C., Goldie, S., Neumann, P.J.: When does quality-adjusted life-years matter in cost-effectiveness analysis. Health Econ. 13, 429–436 (2004)PubMedCrossRef
12.
13.
Briggs, A., Sculpher, M., Claxton, K.: Decision Modelling for Health Economic Evaluation. Oxford University Press, Oxford (2006)
14.
Huber, P.J.: Robust Statistics. Wiley, New York (2004)
15.
Oliva, J., del Llano, J.E., Sacristán, J.A.: The economic evaluation of health care technologies in Spain. Present situation and utility as a guide in allocating health care resources. Inf. Comercial Española 804, 155–167 (2003) (Spanish)
16.
17.
18.
Sacristán, J.A., Rovira, J., Ortún, V., García-Alonso, F., Prieto, L., Antoñanzas, F.: Grupo ECOMED: utilization of economic assessments of health interventions. Med. Clin. 122, 789–795 (2004) (Spanish)CrossRef
19.
Clemente, S., Mendante, L., Montoro, J.B.: Current framework of biotechnology products according to the available pharmacoeconomic studies. Med. Clin. 120, 498–504 (2003) (Spanish)CrossRef
20.
Puig-Junoy, J., Peiró, S.: From the therapeutic utility to the added therapeutic value and the incremental cost-effectiveness ratio. Rev. Esp. Salud Publica 83, 59–70 (2009) (Spanish)PubMedCrossRef
21.
Brosa, M., Gisbert, R., Rodríguez, J.M., Soto, J.: Principles, methods and applications of budgetary impact analysis in the health sector. Pharmacoecon. Span. Res. Articles 2, 64–78 (2005) (Spanish)
22.
Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices-budget impact analysis. Value Health 10, 324–325 (2007)CrossRef
23.
Gil, J.M., Rubio-Terrés, C., Del Castillo, A., González, P., Canorea, F.: Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clin. Transl. Oncol. 8, 339–348 (2006)PubMedCrossRef
24.
Buti, M., Casado, M.A., Fosbrook, L., Wong, J.B., Esteban, R.: Cost-effectiveness of combination therapy for naive patients with chronic hepatitis C. J. Hepatol. 33, 651–658 (2000)PubMedCrossRef
25.
Shearer, A.T., Bagust, A., Ampudia-Blasco, F.J., Alvarez, B.M., Escolano, E.P., Paris, G.: Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. Pharmacoeconomics 24, 49–59 (2006)PubMed
26.
Cairols-Castellote, M.A., Salmerón-Febres, L.M., Fernández-Samos, R., Iborra-Ortega, E., Vaquero-Puerta, C., Marco-Luque, M., Doblas-Domínguez, M., Riera de Cubas, L., Reparaz-Asensio, L.M., Fernández-Valenzuela, V., Crespo, C., Rodríguez, J.M.: Analysis of the cost-effectiveness of using stents to treat abdominal aortic aneurysms in Spain. Angiología 61, 51–61 (2009) (Spanish)CrossRef
27.
Martín-Jiménez, M., Rodríguez-Lescure, A., Ruiz-Borrego, M., Seguí-Palmer, M.A., Brosa-Riestra, M.: Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin. Transl. Oncol. 11, 41–47 (2009)PubMedCrossRef
28.
Oliva, J., López-Bastida, J., Moreno, S.G., Mata, P., Alonso, R.: Cost-effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia. Rev. Esp. Cardiol. 62, 57–65 (2009) (Spanish)PubMedCrossRef
29.
Alonso, R., Fernández de Bobadilla, J., Méndez, I., Lázaro, P., Mata, N., Mata, P.: Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy. Rev. Esp. Cardiol. 61, 382–393 (2008) (Spanish)PubMedCrossRef
30.
Fernández de Bobadilla, J., Sánchez-Maestre, C., Brosa-Riestra, M., Arroyo, O., Sanz de Burgoa, V., Wilson, K.: Cost effectiveness analysis of varenicline (Champix) for the treatment of smoking in Spain. An. Med. Int. 25, 342–348 (2008) (Spanish)
31.
Grupo de Farmacoeconomía del Linfoma Folicular: Rituximab cost analysis for maintenance treatment of patients with follicular lymphoma. Farm. Hosp. 32, 25–34 (2008) (Spanish)CrossRef
32.
Largeron, N., Rémy, V., Oyee, J., San-Martin, M., Cortés, J., Olmos, L.: Cost-effectiveness analysis of vaccination against human papilloma virus (HPV) types 6, 11, 16 and 18 in Spain. Vacunas 9, 3–11 (2008) (Spanish)CrossRef
33.
Maroto, P., Villavicencio, H., Piñol, C., Urruticoechea, L., Brosa, M.: A cost-effectiveness analyses of oral sorafenib in advanced renal cell carcinoma. Rev. Esp. Econ. Salud 7, 173–180 (2008) (Spanish)
34.
Mayordomo, J.I., Lòpez, A., Giménez, E., Badia, X., Lara, N., Sorio, F., Liu, Z., Arocho, R.: Economic evaluation of use of pegfilgrastim versus filgrastim in primary profilaxis in patients with breast cancer with febril neutropenia risk in Spain. Pharmacoecon. Span. Res. Articles 5, 71–81 (2008) (Spanish)
35.
Paz-Ares, L., García del Muro, X., Grande, E., González, P., Brosa, M., Díaz, S.: Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin. Transl. Oncol. 10, 831–839 (2008)PubMedCrossRef
36.
Aballéa, S., De Juanes, J.R., Barbieri, M., Martin, M., Chancellor, J., Oyagüez, I., Verwee, B., Largeron, N.: The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine 28, 6900–6910 (2007)CrossRef
37.
Badia, X., Lizán, L., Magaz, S., Sanz, A.C., Green, J., Serrano, D.: Cost-effectiveness analysis of enfuvirtide added to an optimized therapy compared with an optimized therapy in patients with HIV/AIDS. HIV Clin. Trials 8, 235–245 (2007)PubMedCrossRef
38.
Casado, M.A., Benavides, M., Cajaraville, G., Carreras, M.J., Tabernero, J.M.: Cost-effectiveness analysis and budget impact analysis of the first line therapy for metastatic colorectal cancer in Spain. Rev. Esp. Econ. Salud 6, 106–118 (2007) (Spanish)
39.
Fernández de Bobadilla, J., Calvo, C., Gómez-Gerique, J.A., Lázaro, P., Méndez, I., García, M.: Cost per life year gained of atorvastatin 10 mg in hypertensive Spanish patients with moderate risk: economic evaluation of the ASCOT-LLA study with Spanish costs. Pharmacoecon. Span. Res. Articles 4, 11–24 (2007) (Spanish)
40.
Lázaro, P., Figueras, J., Domenech, E., Closa, R., Echániz, I., Wood, M.A., Fitch, K.: Cost-effectiveness of palivizumab in preventing respiratory syncytial virus in premature infants and children with chronic lung disease in Spain. Pharmacoecon. Span. Res. Articles 4, 59–70 (2007) (Spanish)
41.
López, J.M., Cortés, J., Gil de Miguel, A.: Human papillomavirus tetravalent vaccine cost-effectiveness study. Rev. Esp. Econ. Salud 6, 400–408 (2007) (Spanish)
42.
Piñol, C., Roze, S., Valentine, W., Evers, T.: Cost-effectiveness of the addition of acarbose to the treatment of patients with type-2 diabetes in Spain. Gac. Sanit. 21, 97–104 (2007) (Spanish)PubMedCrossRef
43.
Cornuz, J., Gilbert, A., Pinget, C., McDonald, P., Slama, K., Salto, E., Paccaud, F.: Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob. Control 15, 152–159 (2006)PubMedCrossRef
44.
Fernández de Bobadilla, J., García, M.: Cost-effectiveness analysis of 80 mg atorvastatin versus 40 mg pravastatin in acute coronary syndrome: an economic evaluation based on the PROVE-IT study (Pravastatin or Atorvastatin Evaluation and Infection Therapy). Pharmacoecon. Span. Res. Articles 3, 19–30 (2006) (Spanish)
45.
Fernández de Bobadilla, J., López de Sa, E., Alonso-Troncoso, I., Moreno-Gómez, R., Rubio-Terrés, C., Soto-Alvarez, J.: Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study. An. Med. Int. 23, 213–219 (2006) (Spanish)
46.
Lamotte, M., Piñol, C., Brotons, C., Annemans, L., Guardiola, E., Evers, T., Kubin, M.: Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease. Rev. Esp. Cardiol. 59, 807–815 (2006) (Spanish)PubMedCrossRef
47.
Lázaro y de Mercado, P., Figueras-Aloy, J., Doménech-Martínez, E., Echániz-Urcelay, I., Closa-Monasterolo, R., Wood, M.A., Fitch, K.: The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32–35 weeks in Spain. An. Pediatr. 65, 316–324 (2006) (Spanish)CrossRef
48.
Lenne, X., Diez-Domingo, J., Gil, A., Ridao, M., Lluch, J.A., Dervaux, B.: Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 24, 6980–6989 (2006)PubMedCrossRef
49.
Badia, X., Bueno, H., González-Juanatey, J.R., Valentín, V., Rubio, M.: Short-and long-term cost-effectiveness analysis of adding clopidogrel to standard therapy in acute coronary syndrome patients in Spain. Rev. Esp. Cardiol. 58, 1385–1395 (2005) (Spanish)PubMedCrossRef
50.
Buti, M., San Miguel, R., Brosa, M., Cabasés, J.M., Medina, M., Casado, M.A., Fosbrook, L., Esteban, R.: Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J. Hepatol. 42, 639–645 (2005)PubMedCrossRef
51.
Cannata, J., Díez, A., López, J.M.: Protelos cost-effectiveness study in the prevention of osteoporosis fractures. Rev. Esp. Econ. Salud 4, 146–152 (2005) (Spanish)
52.
Grau, S., Alvarez-Lerma, F., del Castillo, A., Neipp, R., Rubio-Terrés, C.: Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain. J. Chemother. 17, 203–211 (2005)PubMed
53.
Asensi, F., De Jose, M., Lorente, M., Moraga, F., Ciuryla, V., Arikian, S., Casciano, R., Vento, M.: A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 7, 36–51 (2004)PubMedCrossRef
54.
Balmaña, J., Sanz, J., Bonfill, X., Casado, A., Rué, M., Gich, I., Díez, O., Sabaté, J.M., Baiget, M., Alonso, M.C.: Genetic counseling program in familial breast cancer: analysis of its effectiveness, cost and cost-effectiveness ratio. Int. J. Cancer 112, 647–652 (2004)PubMedCrossRef
55.
Brosa, M., Crespo, C.: Cost-effectiveness analysis of clinical management of hyperlipidemia with atorvastatin versus usual care in secondary coronary-hearth disease prevention. Rev. Esp. Econ. Salud 3, 50–56 (2004) (Spanish)
56.
Camacho, J., López, J.M.: Impact of the treatment costs with Advate in the antihaemophilic therapy. Cost-effectiveness analysis. Rev. Esp. Econ. Salud 3, 179–186 (2004) (Spanish)
57.
Cook, J.R., Yin, D., Alemao, E., Davies, G., Krobot, K.J., Veltri, E., Lipka, L., Badia, X.: Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal: application to Germany, Spain and Norway. Pharmacoeconomics 22(Suppl 3), 49–61 (2004)PubMed
58.
Sacristán, J.A., Prieto, L., Huete, T., Artigas, A., Badia, X., Chinn, C., Hudson, P.: Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain. Gac. Sanit. 18, 50–57 (2004) (Spanish)PubMedCrossRef
59.
Antoñanzas, F., Portillo, F.: Economic evaluation of pharmacotherapies for smoking cessation. Gac. Sanit. 17, 393–403 (2003) (Spanish)PubMedCrossRef
60.
Buti, M., Medina, M., Casado, M.A., Wong, J.B., Fosbrook, L., Esteban, R.: A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 17, 687–694 (2003)PubMedCrossRef
61.
Gambús, G., Espinosa, C.: Cost-effectiviness analysis of fluvastatin in patients with coronary heart disease after percutaneus coronary intervention. Rev. Esp. Econ. Salud 2, 327–330 (2003) (Spanish)
62.
Moreno, A., Vargas, E., Soto, J., Rejas, J.: Cost-effectiveness analysis of the use of celecoxib for the treatment of osteoarthritis. Gac. Sanit. 17, 27–36 (2003) (Spanish)PubMedCrossRef
63.
Nuijten, M.J., Villar, F.A., Kosa, J., Nadipelli, V., Rubio-Terrés, C., Suarez, C.: Cost-effectiveness of enoxaparin as thromboprophylaxis in acutely ill medical patients in Spain. Value Health 6, 126–136 (2003)PubMedCrossRef
64.
San Miguel, R., Mar, J., Cabasés, J.M., Guillén-Grima, F., Buti, M.: Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment. Pharmacol. Ther. 17, 765–773 (2003)PubMedCrossRef
65.
Hart, W.M., Rubio-Terrés, C., Burrell, A., Arístegui, I., Escobar-Jiménez, F.: Pharmacoeconomic analysis of the treatment of postmenopausal osteoporosis with risedronate or alendronate. Reemo 11, 97–104 (2002) (Spanish)
66.
Hart, W.M., Rubio-Terrés, C., Margalet-Fernández, I., González-Juanatey, J.R.: Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain. An. Med. Int. 19, 515–520 (2002) (Spanish)
67.
Hart, W.M., Rubio-Terres, C., Pajuelo, F., González-Juanatey, J.R.: Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study. Eur. J. Heart Fail. 4, 553–558 (2002)PubMedCrossRef
68.
Lindgren, P., Jönsson, B., Redaelli, A., Radice, D.: Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia. Pharmacoeconomics 20, 101–108 (2002)PubMedCrossRef
69.
Llovet, J.M., Mas, X., Aponte, J.J., Fuster, J., Navasa, M., Christensen, E., Rodés, J., Bruix, J.: Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50, 123–128 (2002)PubMedCrossRef
70.
Plans, P.: Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain). Gac. Sanit. 16, 392–400 (2002) (Spanish)PubMed
71.
Antoñanzas, F.A., Botella, F.A.: Economic evaluation of eptifibatide. Rev. Esp. Cardiol. 54, 169–174 (2001) (Spanish)
72.
Soto-Alvarez, J., González-Vilchez, F.: Cost effectiveness of the use of spironolactone in the treatment of chronic heart failure. An. Med. Int. 18, 421–425 (2001) (Spanish)
73.
González-Larriba, J.L., Serrano, S., Alvarez-Mon, M., Camacho, F., Casado, M.A., Díaz-Pérez, J.L., Díaz-Rubio, E., Fosbrook, L., Guillem, V., López-López, J.J., Moreno-Nogueira, J.A., Toribio, J.: Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain. Eur. J. Cancer 36, 2344–2352 (2000)PubMedCrossRef
74.
Berger, K., Fischer, T., Szucs, T.D.: Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur. J. Cancer 34, 1894–1901 (1998)PubMedCrossRef
75.
Comas-Fuentes, A., Suárez-Gutiérrez, R., López-González, M.L., Cueto-Espinar, A.: Cost-effectiveness of antismoking health counseling in primary health care. Gac. Sanit. 12, 126–132 (1998) (Spanish)PubMed
76.
Plans-Rubió, P.: Cost-effectiveness analysis of treatment to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease; evaluative study carried out in Spain. Pharmacoeconomics 13, 623–643 (1998)PubMedCrossRef
77.
Plans-Rubió, P.: Cost-effectiveness of cardiovascular prevention programs in Spain. Int. J. Technol. Assess. Health Care 14, 320–330 (1998)PubMedCrossRef
78.
Garuz, R., Forcen, T., Cabases, J., Antonanzas, F., Trinxet, C., Rovira, J., Anton, F.: Economic evaluation of a mammography-based breast cancer screening programme in Spain. Eur. J. Public Health 7, 68–76 (1997)CrossRef
79.
Rubió, P.: Cost-effectiveness of dietary treatment of hypercholesterolemia in Spain. Public Health 111, 33–40 (1997)PubMedCrossRef
80.
Plans, P., Casademont, L., Tarín, A., Navas, E.: The study of cost effectiveness of breast cancer detection in Catalonia. Rev. Esp. Salud Publica 70, 15–23 (1996) (Spanish)PubMed
81.
Plans, P., Navas, E., Tarín, A., Rodríguez, G., Galí, N., Gayta, R., Taberner, J.L., Salleras, L.: Cost-effectiveness of the methods of smoking cessation. Med. Clin. 104, 49–54 (1995) (Spanish)
82.
Plans-Rubió, P., Garrido-Morales, P., Salleras-Sanmartí, L.: The cost-effectiveness of pneumococcal vaccination in Catalonia. Rev. Esp. Salud Publica 69, 409–417 (1995) (Spanish)PubMed
83.
Plans-Rubió, P., Rovira-Forns, J.: Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids. Med. Clin. 105, 327–333 (1995) (Spanish)
84.
Badía, X., Segú, L., García-Alonso, F., Rovira, J.: A cost-efficacy analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis. Med. Clin. 100, 84–89 (1993) (Spanish)
Metadata
Title
The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications
Authors
José Manuel Rodríguez Barrios
Ferran Pérez Alcántara
Carlos Crespo Palomo
Paloma González García
Enrique Antón De Las Heras
Max Brosa Riestra
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue 6/2012
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-011-0326-y

Other articles of this Issue 6/2012

The European Journal of Health Economics 6/2012 Go to the issue

Editorial

The Grossman model after 40 years

Original Paper

Health care usage among immigrants and native-born elderly populations in eleven European countries: results from SHARE

Original Paper

Paying informally in the Albanian health care sector: a two-tiered stochastic frontier model

Original Paper

Patients whose GP knows complementary medicine tend to have lower costs and live longer

Original Paper

Cost effectiveness of golimumab for the treatment of active psoriatic arthritis

Original Paper

The cost-effectiveness of cash versus lottery incentives for a web-based, stated-preference community survey